Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials

Solriamfetol is developed for the treatment of excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea (OSA). No systematic review of existing literature has been investigated before. Therefore, the meta-analysis is conducted to assess the efficacy and safety of solriamfet...

Full description

Saved in:
Bibliographic Details
Published in:Sleep medicine 2021-03, Vol.79, p.40-47
Main Authors: Wang, Jiahe, Yang, Siyuan, Li, Xiang, Wang, Tianyi, Xu, Zhongmou, Xu, Xiang, Gao, Heng, Chen, Gang
Format: Article
Language:English
Subjects:
Excessive sleepiness
Meta-analysis
Narcolepsy
Obstructive sleep apnea
Solriamfetol
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Solriamfetol is developed for the treatment of excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea (OSA). No systematic review of existing literature has been investigated before. Therefore, the meta-analysis is conducted to assess the efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and OSA. PubMed, Embase and Cochrane Library databases were searched from earliest date to July 2020 for randomized controlled trials (RCTs) and the primary outcomes were change from baseline in mean sleep latency and Epworth Sleepiness Scale (ESS). We pooled 1177 patients from five RCTs and found solriamfetol led to a significant increment in mean sleep latency (MD = 9.52, 95% CI: 7.60 to 11.44, P 
ISSN:1389-9457
1878-5506
DOI:10.1016/j.sleep.2020.12.039